CPHI Online is part of the Informa Markets Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Home CPC Scientific Inc. and UNC Lineberger Comprehensive Cancer Center Announce Neoantigen Peptide Collaboration to Manufacture Neoantigen Peptides for the PANDA (Personalized and Adaptive) Cancer Vaccine Program.
News
7 Mar 2019

CPC Scientific Inc. and UNC Lineberger Comprehensive Cancer Center Announce Neoantigen Peptide Collaboration to Manufacture Neoantigen Peptides for the PANDA (Personalized and Adaptive) Cancer Vaccine Program.

CPC Scientific Inc., a leading global CDMO specializing in synthetic peptide manufacturing, announced today that they will manufacture GMP-grade neoantigen peptides for investigators at UNC Lineberger Comprehesive Cancer Center (LCCC) for the purpose of individualized immunotherapy.

CPC Scientific will supply GMP-grade neoantigen peptides, the sequences of which will be determined via genomics and bioinformatics, for use in the LCCC therape..

Mentioned Companies
CPC Scientific Inc.
View company profile